Earnings ·
Sera Prognostics reported second quarter 2026 financial results with revenue of $30,000 compared to $17,000 in the…
SERASera Prognostics, Inc.
Sera Prognostics reported second quarter 2026 financial results with revenue of $30,000 compared to $17,000 in the prior year period. Total operating expenses were $10.0 million against $9.3 million previously, resulting in a net loss of $9.1 million versus an $8.0 million loss last year. The company ended the quarter with approximately $80.3 million in cash and securities. Key operational highlights include launching a fourth partnership program for its PreTRM test-guided care strategy, exceeding 2026 payer engagement objectives across more than 20 states, and Illinois enacting legislation mandating Medicaid coverage for preterm birth risk testing affecting approximately 50,000 annual births. Additionally, the company appointed Mark Capone to its Board of Directors and published PRIME study data demonstrating a 22% reduction in NICU admissions among first-time mothers. Sera Prognostics operates in the healthcare diagnostics industry, providing pregnancy biomarker tests to assess preterm birth risk.